Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?

Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?, Published online: 04 February 2019; doi:10.1038/s41397-019-0078-0Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?

Source: The Pharmacogenomics Journal - February 4, 2019 Category: Drugs & Pharmacology Authors: Federico Nichetti Felicia Stefania Falvella Rosalba Miceli Stefania Cheli Raffaella Gaetano Giovanni Fuc à Gabriele Infante Antonia Martinetti Carlotta Antoniotti Alfredo Falcone Maria Di Bartolomeo Chiara Cremolini Filippo de Braud Filippo Pietrantonio Source Type: research